A carregar...
Novel Humanitarian Aid Program: The Glivec International Patient Assistance Program—Lessons Learned From Providing Access to Breakthrough Targeted Oncology Treatment in Low- and Middle-Income Countries
Imatinib was the first targeted therapy approved for the treatment of cancer. With its approval, it was immediately clear to Novartis that this breakthrough therapy would require an innovative approach to worldwide access, with special consideration of low- and middle-income countries. Lack of gover...
Na minha lista:
| Publicado no: | J Glob Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Clinical Oncology
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5551649/ https://ncbi.nlm.nih.gov/pubmed/28804770 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JGO.2015.000570 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|